Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02027662

Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules (OsvaRenNEW)

Study to Investigate Efficacy and Safety Equivalence of OsvaRen® Tablets and OsvaRen® Granules

Sponsor: Fresenius Medical Care Deutschland GmbH

Conditions Chronic Kidney Disease Hyperphosphatemia

Interventions Osvaren Granules Osvaren film-coated tablets

Updated 6 times since 2017 Last updated: Jun 9, 2015 Started: Jan 31, 2014 Primary completion: Apr 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Chronic Kidney Disease and Hyperphosphatemia, this trial is completed. The trial is conducted by Fresenius Medical Care Deutschland GmbH and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fresenius Medical Care Deutschland GmbH

Data source: Fresenius Medical Care Deutschland GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Erfurt, Germany , Flensburg, Germany , Giessen, Germany , Hamburg, Germany , Hanover, Germany , Kiel, Germany , Magdeburg, Germany , Minden, Germany , Solingen, Germany and 1 more location